Skip to Main Content

Paper Details

Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells.
BMC Cancer
16
2018
3-phosphoinositide dependent protein kinase-1, BMX, BMX non-receptor tyrosine kinase, CONCLUSION, CSC, Cy5, EGF, LRCC, LRCC population, Label-retaining cancer cells, NLRCC, NTRK2, PDPK1, Pancreatic cancer, Pancreatic cancer cell, Pancreatic cancer cell-derived LRCC, bulk, bulk tumor cells, cancer, dUTP, epidermal growth factor, gemcitabine, label-retaining pancreatic cancer cells, neurotrophic, non, non-, non-LRCC, pancreas cancer, pancreatic cancer, pancreatic cancer cell lines, patients, receptor tyrosine kinase 2, slowly cycling cancer stem cells, tumor, tumor cell population, tumor cells, tumor samples, tumors, tyrosine, upregulated
Author NameAffiliation
Snorri S ThorgeirssonCenter for Cancer Research, National Cancer Institute
Itzhak AvitalSt. Peter's Hospital, Rutgers University, Robert Wood Johnson School of Medicine
Itzhak AvitalSt. Peter's Hospital, Rutgers University, Robert Wood Johnson School of Medicine
Udo RudloffNational Cancer Institute
Udo RudloffNational Cancer Institute
  • 1 - 5

Datasets

Release 1.2